Status:
RECRUITING
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
Lead Sponsor:
ENA Respiratory Pty Ltd
Conditions:
Viral Respiratory Infection
Viral Respiratory Illnesses
Eligibility:
All Genders
18-45 years
Phase:
PHASE2
Brief Summary
Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the invest...
Detailed Description
Viral respiratory infections are associated with significant morbidity and mortality. The diversity of viruses, along with their propensity for mutation, ignited an interest in host-directed therapies...
Eligibility Criteria
Inclusion
- In good general health and without clinically significant medical, psychiatric, chronic or intermittent health conditions.
- At risk for exposure to viral respiratory infection, for example, living in crowded housing, university housing, or military barracks, working in a childcare center or caring for a child aged 10 or less, healthcare workers, factory workers, taxi and bus drivers, grocery clerks, and educators or counselors who work in crowded environments or with multiple exposures with different people daily.
- Agree to use highly effective birth control.
Exclusion
- Presence of Type I or Type II diabetes, asthma or other chronic respiratory condition.
- Active infections including Hepatitis B Virus, Hepatitis C Virus, or Human Immunodeficiency (HIV).
- Concurrent participation in another clinical trial involving investigational product or prior receipt of investigational product within 90 days or 5 half-lives of the product.
- Active clinical signs or symptoms of acute respiratory illness (runny nose, sore throat, fever, etc.).
- Received a vaccine against Respiratory Syncytial Virus (RSV) or COVID-19 within 180 days.
- Pregnant or lactating women.
Key Trial Info
Start Date :
December 4 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 9 2027
Estimated Enrollment :
1100 Patients enrolled
Trial Details
Trial ID
NCT07222670
Start Date
December 4 2025
End Date
February 9 2027
Last Update
December 15 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Vaccine Development and Global Health (CVD)
Baltimore, Maryland, United States, 21201
2
Naval Medical Research Command (NMRC)
Bethesda, Maryland, United States, 20889
3
Accellacare of Raleigh
Raleigh, North Carolina, United States, 27609
4
Accellacare of Piedmont HealthCare
Statesville, North Carolina, United States, 28625